Immortalized Cell Line Market Research Report - Global Forecast till 2027

Immortalized Cell Line Market Research Report: Information by Method (Virus Induction, HTERT Expression, Inactivation of Tumor Suppression Genes and others), Application (Diagnostics, Drug Discovery, Vaccine Production, Tissue Engineering and Regenerative Medicines and others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations and Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/LS/0267-CR | August 2019 | Region: Global | 130 pages         

Immortalized Cell Line Market Speak to Analyst Request a Free Sample

The Immortalized Cell Line Market is expected to register 9.30CAGR and is anticipated to reach USD 4,105.62 Million by 2023. Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies.


Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.


The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.


Market Dynamics


The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.


Immortalized Cell Line Market Size, by End User, 2017 (USD Million)  Immortalized Cell Line Market


Source: MRFR Analysis


Segmentation


The immortalized cell line market has been segmented into method, application, and end user. 


Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.


The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.


Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.  


Key Players


The prominent players in the immortalized cell line market are Thermo Fisher Scientific (US), ATCC (American Type Culture Collection Inc.) (US), Valneva (France), Sartorius AG (Germany), Lonza Group, AG (Switzerland), Merck KGaA (Germany), Selexis SA (Switzerland), WuXi App Tec (China), European Collection of Authenticated Cell Cultures (ECACC) (Europe), and Corning Incorporated (US)


Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.


Immortalized Cell Line Market Share, by Region, 2017 (%)  Immortalized Cell Line Market


Source: MRFR Analysis


Regional Analysis


The immortalized cell line market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.


The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.    


Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.


The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.


Key Updates



  • In April 2018, Lonza Group, AG announced the opening of the world’s largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Greater Houston, TX (US). The manufacturing site was built in anticipation of the rising demand from developers of cell and gene therapies.



  • In August 2017, Thermo Fisher Scientific acquired Patheon for 7.2 USD million. Patheon’s CDMO services are likely to complement Thermo Fisher Scientific’s life sciences technologies designed to support research, clinical trials, and production.


Market Segmentation


Immortalized Cell Line Market, by Method



  • Virus Induction


    • EBV genes

    • SV40 T antigen

    • HPV-16 E6/6 gene

    • Others 


  • HTERT Expression


    • P53

    • Myc T58A


  • Inactivation of Tumour Suppression Genes

  • Others


Immortalized Cell Line Market, by Application



  • Diagnostics

  • Drug Discovery

  • Vaccine Production

  • Tissue Engineering and Regenerative Medicines

  • Others


Immortalized Cell Line Market, by End User



  • Pharmaceutical and Biopharmaceutical Companies

  • Contract Research Organizations

  • Research Laboratories


Immortalized Cell Line Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • South America




  • Europe


    • Western Europe


      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • China

    • Japan

    • India

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Research and development (R&D) companies

  • Government research institutes

  • Academic institutes and universities



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Immortalized Cell Line Market is predicted to touch USD 4,105.62 million by 2023.

Immortalized Cell Line Market is projected to grow at a 9.30% CAGR between 2020-2027.

North America is projected to dominate the Immortalized Cell Line Market.

Pharmaceutical & biopharmaceutical companies will dominate the Immortalized Cell Line Market.

Increasing prevalence of cancer, growing need for organ transplantation, and rising application in hospitals, pharmaceutical & biotech companies are boosting market growth.

Global Immortalized Cell Line Market: Competitive Landscape


Lonza Group AG, Corning Incorporated, Thermo Fisher Scientific, and Selexis SA collectively accounted for more than 65.1% of the market share of the global immortalized cell line market in 2017. These companies continue to retain their strong global presence through expansions, mergers & acquisitions, and agreements.


In 2017, Lonza Group AG was the leading player in the market. The company pursued a strategy of acquisitions and expansions to strengthen its position in the global market. The company leverages its expertise in pharmaceuticals and biotech and specialty ingredients to develop new products. The company has a strong foothold with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. Its dominance is likely to remain unchallenged during the assessment period.


Corning Incorporated held the second position in terms of market share, in 2017. It focuses on its strategic decision to work on flexible business models to enable customized solutions to satisfy the unique needs of clients. The company is the innovator in medical science, with expertise in glass science, ceramic science, and optical physics. The company has its research centers in North America, Europe, and Asia. The firm has its products manufactured in over 17 countries. Moreover, it also works in the segment that provides innovative solutions, improving improve productivity and enabling breakthrough discoveries in life science division.


Thermo Fisher Scientific acquired the third spot in the market. The company is focused on technically magnificent products and skilled workforce, which assists its customers to accelerate life science research as well as getting better outcomes in challenging clinical research fields. It also focusses on the pricing of products to provide attractive volume expansion opportunities. The company has adopted the strategy of acquisitions to increase its share in the market. For this, the company acquired Patheon for USD 7.2 million. Patheon’s CDMO services are likely to complement Thermo Fisher Scientific’s life sciences technologies designed to support research, clinical trials, and production.


Selexis SA is one of the most competitive players in this market. The company is engaged in providing mammalian cell-line generation technologies to facilitate the development and translation of new therapies into life-saving medicines. Additionally, the company provides cell-line development, lead identification, and genomic characterization services. The company focuses on providing breakthrough technologies fundamentally impacting and improving drug discovery, drug development, and biopharmaceutical manufacturing.


In the near future, the strategies to gain a significant market share in this growing industry have been varying from acquisitions and agreements to expansions. The established companies are busy in acquiring companies and entering into the agreement with other ecosystem players. Acquisitions are a key focus area for players as the demand for cost-effective and efficient immortal cell lines for numerous applications such as drug discovery, vaccine production, diagnosis, and tissue regeneration, among others is growing rapidly. This surges the growth of the global immortalized cell line market.